In a report released yesterday, Hartaj Singh from Oppenheimer assigned a Buy rating to F-star Therapeutics (FSTX), with a price target of $30.00. The company’s shares closed last Monday at $6.74.
According to TipRanks.com, Singh is a 4-star analyst with an average return of 13.6% and a 45.5% success rate. Singh covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Catabasis Pharmaceuticals, and Alexion Pharmaceuticals.
F-star Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $32.33.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.
